BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst鈥檚 board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 47,250 shares of BioCryst common stock. The RSUs were granted as of June 2, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee鈥檚 continued service with the company. The RSUs are subject to the terms and conditions of BioCryst鈥檚 Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO庐 (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on .
BCRXW
Contact:
John Bluth
+1 919 859 7910
FAQ
How many RSUs did BioCryst (BCRX) grant to new employees in June 2025?
What is the vesting schedule for BioCryst's June 2025 RSU grants?
Under which Nasdaq rule were BioCryst's June 2025 RSUs granted?
What conditions apply to BioCryst's June 2025 RSU grants?
